Oral Ketamine vs placebo in patients with cancer-related neuropathic pain:a randomized clinical trial by Fallon, Marie T. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oral Ketamine vs placebo in patients with cancer-related
neuropathic pain
Citation for published version:
Fallon, M, Wilcock, A, Kelly, C, Paul, J, Lewsley, L-A, Norrie, J & Laird, B 2018, 'Oral Ketamine vs placebo
in patients with cancer-related neuropathic pain: a randomized clinical trial' JAMA Oncology. DOI:
10.1001/jamaoncol.2018.0131
Digital Object Identifier (DOI):
10.1001/jamaoncol.2018.0131
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
JAMA Oncology
Publisher Rights Statement:
This is an open access article distributed under the terms of the CCBY
License.©2018 Fallon MT et al. JAMA Oncology.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 30. Jun. 2018
Letters
RESEARCH LETTER
Oral Ketamine vs Placebo in Patients
With Cancer-RelatedNeuropathic Pain:
A Randomized Clinical Trial
Ketamine hydrochloride is used as an adjuvant treatment
for cancer-related neuropathic pain, but evidence of its
effectiveness is limited.1 Findings of a large trial investigat-
ing the use of ketamine for general cancer pain were nega-
tive, but the population
studied did not specifically
have neuropathic pain.2 A
randomized trial of oral ketamine for cancer-related neuro-
pathic pain has been called for,3 and the present trial
addresses that need.1
Methods | A multicenter, double-blind randomized clinical
trial of oral ketamine vs placebo was conducted in the
United Kingdom cities of Edinburgh, Glasgow, Nottingham,
and Lancashire in adults with cancer-related neuropathic
pain, which was defined using set criteria (Leeds Assessment
of Neuropathic Symptoms and Signs). Patients had previ-
ously been treated with adjuvant analgesics for neuropathic
pain, which had been ineffective or suboptimal. Preexisting
analgesia was continued throughout the trial. Patients were
centrally randomized using minimization, then ketamine or
placebo was titrated across 2 weeks to an effective and toler-
able dosage (Figure). The starting dosage was 40 mg/d, with
a maximum dosage of 400 mg/d. Patients continued to
receive a stable dosage for 16 days. Patients who did not
experience an analgesic benefit were withdrawn from the
Figure. CONSORT Study FlowDiagram
513 Patients assessed for eligibility
107 Randomized to receive ketamine hydrochloride 107 Randomized to receive placebo
49 Entered pain-control maintenance phase 50 Entered pain-control maintenance phase
24 Completed pain control maintenance phase with no
treatment failure
26 Completed pain control maintenance phase with no
treatment failure
296 Excluded
115 Ineligible
65 Investigator decision
57 Declined to participate-other
29 Too unwell
21 Declined to participate-placebo
9 Conflicting trial
3 Did not participate beyond run-in phase
2 Withdrew: achieved pain control during run-in
1 Unable to comply
57 Excluded for treatment failures during
titration phase
41 Investigator declared treatment
failure
16 Failure to achieve ≥5-point
improvement in index pain by end
of titration phase
0 >30% Increase in 24-h MEDD of
opioid
24 Excluded for treatment failures
during pain-control maintenance phase
17 Failure to achieve ≥5-point
improvement in index pain by end
of titration phase
7 Investor declared treatment failure
0 >30% Increase in 24-h MEDD
of opioid
58 Excluded for treatment failures
during titration phase
31 Investigator declared treatment
failure
26 Failure to achieve ≥5-point
improvement in index pain by end
of titration phase
1 >30% Increase in 24-h MEDD of
opioid
25 Excluded for treatment failures
during pain-control maintenance phase
18 Failure to achieve ≥5-point
improvement in index pain by end
of titration phase
5 Investigator declared treatment
failure
2 >30% Increase in 24-h MEDD
of opioid
214 Randomized
Among the 107 patients randomized
to ketamine, themedian
(interquartile range [IQR]) time spent
in the titration phase for the 58
patients who experienced treatment
failure and were excluded was 14
(14-14) days; range, 7 to 28 days. Of
the 49 patients who entered the
pain-control maintenance phase, the
median (IQR) time spent in the
titration phase was 14 (14-15) days;
range, 8 to 21 days. Among the 107
patients randomized to placebo, the
median (IQR) time spent in the
titration phase for the 57 patients
who experienced treatment failure
and were excluded was 14 (12.5-14.0)
days; range, 0 to 22 days. Of the 50
patients who entered the
pain-control maintenance phase, the
median (IQR) time spent in the
titration phase was 14 (14-15) days;
range, 5 to 20 days. MEDD indicates
morphine-equivalent daily dose.
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study. The study was approved by the West of Scotland Mul-
ticentre Research Ethics Committee (the full trial protocol is
available in the Supplement; isrctn.org Identifier:
ISRCTN49116945 and clinicaltrialsregister.eu Identifier:
2007-002080-27), and participants provided written
informed consent.
The primary end point was duration of analgesic benefit,
defined as an improvement of 5 points or more in the index
pain score (using the Sensory Component of the Short Form
McGill PainQuestionnaire), comparedwith thebaseline score
during the 16 days of receiving a stable dosage of ketamine or
placebo. Patients inwhom titration failedwere considered to
haveadurationof0days.Maintenanceofanalgesicbenefitwas
considered to have failed in patients whose opioid dosage in-
creasedduring this time. Secondaryendpoints includedmean
andworstpain;mood (HospitalAnxietyandDepressionScore,
a self-administered anxiety anddepression screening tool for
use in nonpsychiatric patients. The tool has 14 items, which
focus on the emotional and cognitive aspects of each aspect.
Each item is scored from 0 to 3 for a combined maximum of
21 for eachaspect,withhigher scores reflectingahigher symp-
tom load); mean change in global distress in the last 24 hours
(NationalComprehensiveCancerNetworkDistressThermom-
eter, which uses a scale of 0 to 10, where 0 is no distress and
10 is extreme distress); quality of life (EuroQoL Thermom-
eter, a patient-rated assessment of present quality of life com-
prising5questions, eachassignedavalueof0 to2points,with
higher values representing better quality of life. The sum of
these responses produces a score on a scale of 0 to 10, which
is then translated into a scale of 0 to 100); and serious ad-
verse events (NationalCancer Institute, CommonToxicityCri-
teria for Adverse Events version 3.0, which provides clini-
cians with descriptive terminology for reporting adverse
events. Each adverse event is graded on a scale of 1 to 5, with
higher grades representing greater severity).
An intention-to-treat approach was used, with a sample
size of 107 patients per arm providing 80% or greater power
to detect an improvement in the duration of analgesic ben-
efit while receiving ketamine corresponding to a 20%
increase in patients in whom analgesic benefit was main-
tained at 16 days (maximum hazard ratio [HR], 0.58). To
compare duration of analgesic benefit, we used Cox propor-
tional hazards regression with a confirmatory log-rank test.
Secondary end points were analyzed using parametric and
nonparametric methods. Quality of life data were analyzed
by calculating the mean of the area under the curve over the
time in the study after adjusting for the baseline value. All P
values are 2-tailed, and P < .05 was statistically significant.
Statistical analyses were performed using SPSS version 22.0
for Windows (IBM).
Results |Twohundred fourteenpatients (median [IQR] age, 58
[51-66]years; 141 [65.8%] female)were randomized,withcom-
parable demographic features between arms (Figure). A vari-
ety of cancer types were represented; however, in 160 pa-
tients (74.7%) the cancer was in remission, andmost of these
patients had chronic, chemotherapy-induced, neuropathic
pain.Twohundredninepatients (97.6%)were following treat-
ment regimens for neuropathic pain.Data ondurationof neu-
ropathic pain were not collected. The median morphine-
equivalent daily dose for both arms was 0 mg. There was no
difference in the duration of analgesic benefit between arms
as assessed by the adjusted (minimization factors) Cox pro-
portional hazardsmodel (ketamine to placebo HR, 0.95 (95%
CI,0.70-1.29);P = .75), supportedby the log-rank test (P = .69).
Themedian duration of analgesic benefit was 0 days (95%CI,
0-1 day) for ketamine and 0 days (95% CI, 0-4 days) for pla-
cebo. To illustrate, 34 of 107 patients (31.8%) receiving ket-
amine vs 39 of 107 (36.4%) receiving placebo maintained an-
algesic benefit at day 4 of the stable dosage (95% CI for
Table. Secondary Outcomes and AUCAnalyses for Distress, Quality of Life, andMood
Variable
Ketamine
Hydrochloride Placebo
Median Difference,
Ketamine − Placebo (95% CI)a
P Value
Secondary
Outcomes
AUC Analyses
Unadjustedb Adjustedc
Secondary Outcomes
Patients with analgesic benefit
at day 4, %
34 (31.8) 39 (36.4) NA .47 NA NA
Patients with an analgesic benefit
at day 16, %
24 (22.4) 27 (25.2) NA .63 NA NA
AUC Analysesd,e
NCCN Distress Thermometer −2.972 −3.053 0.081 (−0.500 to 0.833) NA .64 .92
EuroQoL Thermometer −17.756 −20.279 2.523 (−5.667 to 9.250) NA .89 .92
Hospital Anxiety
and Depression Score
Anxiety score −3.605 −3.625 0.020 (−1.417 to 1.250) NA .65 .92
Depression score −3.481 −3.654 0.173 (−0.500 to 0.958) NA .66 .92
Abbreviations: AUC, area under the curve; NA, not applicable; NCCN, National
Comprehensive Cancer Network.
a Estimated using 100000 bootstrap samples.
bDetermined using theMann-Whitney test.
c Adjusted for multiple testing (false-discovery rate method).
dMissing data were imputed (last observation carried forward) for the AUC
analyses only.
e Descriptions, scales, and possible range of scores for the NCCN Distress
Thermometer, EuroQoL Thermometer, and Hospital Anxiety and Depression
Score can be found in theMethods section of this research letter.
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difference, −17% to8%). Corresponding figures at day 16were
24 of 107 patients (22.4%) receiving ketamine and 27of 107
(25.2%) receivingplacebo (95%CI fordifference, −14%to9%).
There were no differences between arms among the second-
ary outcomes (Table).
Therewere 18 serious adverse events: 8 inpatients receiv-
ing ketamine and 10 in patients receiving placebo. Common
adverse events were cognitive disturbance, dizziness, fa-
tigue, nausea, and somnolence.
Discussion | This trial reports that ketamine was equivalent to
placebo for cancer-related neuropathic pain. Findings en-
hance previous work4 by examining ketamine in cancer-
related neuropathic pain. There may be subgroups of pa-
tients forwhomketamine ishelpful, suchas thosewith central
sensitization.A limitationof thepresent studywas thatwedid
not specifically select patients with clinical evidence of cen-
tral sensitization, for whom it is reasonable to hypothesize a
morespecific analgesic target forketamine.Future studies that
examine ketamine in chronic neuropathic pain should focus
on patients with central sensitization, which can be estab-
lishedbyabedsidetest.Thisapproachwouldbecongruentwith
preclinical knowledge and would address an important re-
maining unanswered question.5
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